Abstract: The present invention concerns the biotechnology sector and more specifically human healthcare. In particular, the present invention describes a vaccine composition for therapeutic use thereof on cancer patients. The vaccine composition described in the present invention has as active principle a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and are combining protein P64k. In addition, specific conditions are described for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. In another embodiment, the present invention concerns a method for purification of the chemical conjugate which not only provides greater purity for the therapeutic composition, but surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans.
Abstract: The present invention is related to the obtaining of modified antibodies by means of DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3), produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026, and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10), produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specifically binding the antigen of the original antibodies, but being at the same time less immunogenic.
Type:
Grant
Filed:
March 19, 2009
Date of Patent:
June 24, 2014
Assignee:
Centro de Inmunologia Molecular (CIM)
Inventors:
Cristina Maria Mateo De Acosta Del Rio, Josefa Lombardero Valladares, Lourdes Tatiana Roque Navarro, Alejandro Lopez Requena
Abstract: Vaccine compositions in which gangliosides and the OMP of N. meningitidis were combined to form very small size proteoliposomes (VSSP) to be administered subcutaneously are described, these compositions do not require the use of any additional adjuvant. The described compositions allow the immunological treatments with gangliosides, particularly N-AcGM3/VSSP and N-GcGM3/VSSP, showing advantages due to the less aggressive reaction in the site of injection and can be used in a simpler way and better for the patients.
Type:
Grant
Filed:
February 27, 2004
Date of Patent:
November 26, 2013
Assignee:
Centro de Inmunologia Molecular (CIM)
Inventors:
Luis Enrique Fernández Molina, Circe Mesa Pardillo
Abstract: The present invention relates generally to polypeptides whose primary sequence has high sequence homology with human interleukin 2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the present invention have an immunomodulatory effect on the immune system, which is selective/preferential on regulatory T cells. The present invention also relates to specific polypeptides whose amino acid sequence is disclosed herein. In another aspect the present invention relates to pharmaceutical compositions comprising as active ingredient the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their immune modulating effect on diseases such as cancer and chronic infectious diseases.
Type:
Application
Filed:
November 26, 2010
Publication date:
December 13, 2012
Applicant:
CENTRO DE INMUNOLOGIA MOLECULAR (CIM)
Inventors:
Kalet León Monzón, Tania Carmenate Portilla, Karina García Martínez, Agustin Bienvendo Lage Davila, Samuel Pérez Rodríguez, Diamile González Roche, Gabriel Márquez Perera
Abstract: Monoclonal antibodies that recognize the CD6 antigen, pharmaceutical compositions that recognizes and that are able to achieve a clinical and histological effectivity in patients with different clinical types of Psoriasis.
Type:
Grant
Filed:
December 17, 1997
Date of Patent:
June 3, 2003
Assignee:
Centro de Inmunologia Molecular (CIM)
Inventors:
Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez, Patricia Sierra Blazquez, Rosa Blanca Tormo Bravo
Abstract: The present invention is related with the field of immunology and human medicine, particularly with the generation and selection of a monoclonal antibody (Mab) that recognizes the N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence presents in malignant tumors.
One of the objectives of this invention is to provide a Mab of the IgG1 type that has the characteristic of recognizing with high specificity N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence presents in malignant tissues of breast, melanomas and tumors of the liver, stomach, colon, rectum and kidneys. It also has the capacity of producing direct cytolysis of the tumoral cells bearing the N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence, thus can be used for the diagnosis and treatment of certain neoplasic diseases.
Type:
Grant
Filed:
November 22, 1999
Date of Patent:
August 6, 2002
Assignee:
Centro de Inmunologia Molecular (CIM)
Inventors:
Adriana Carr Pérez, Zaima Mazorra Herrera, Luis Enrique Fernández Molina, Ana Maria Vázquez López, Ailette Mulet Sierra, Rolando Pérez Rodríguez